Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
31.33
+0.03 (+0.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
Wednesday Market Coverage
October 20, 2021
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.
Via
Talk Markets
Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics
October 20, 2021
Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong...
Via
Benzinga
Exposures
COVID-19
AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial
October 20, 2021
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
October 20, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19...
Via
Benzinga
Bitcoin Futures Arrive
October 19, 2021
Today you can finally hold Bitcoins via an exchange-traded fund.
Via
Talk Markets
Why Atea Pharmaceuticals Is Imploding Today
October 19, 2021
The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.
Via
The Motley Fool
Exposures
COVID-19
Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test
October 19, 2021
Atea Pharmaceuticals said its Covid pill didn't lower viral loads in all patients.
Via
Investor's Business Daily
David v Goliath in The Race to Develop an Oral Therapy for COVID-19
October 19, 2021
Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19...
Via
Benzinga
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio
October 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...
Via
Benzinga
Why Are Atea Pharmaceuticals Shares Plunging Today?
October 19, 2021
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate...
Via
Benzinga
Chinese Growth Level
October 18, 2021
The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.
Via
Talk Markets
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops
October 18, 2021
Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal.
Via
Investor's Business Daily
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
October 18, 2021
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with...
Via
Benzinga
Exposures
Product Safety
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
Exposures
Product Safety
Crispr: A Fallen Angel In Gene Editing
October 16, 2021
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...
Via
Talk Markets
Europe's Unicorns
October 15, 2021
After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.
Via
Talk Markets
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers
October 14, 2021
You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based...
Via
Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
October 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...
Via
Benzinga
Exposures
COVID-19
Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio?
October 11, 2021
You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB...
Via
Talk Markets
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
October 11, 2021
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK...
Via
Benzinga
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation
October 08, 2021
Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is...
Via
Benzinga
Exposures
Product Safety
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst
October 06, 2021
Merck & Co., Inc. (NYSE:MRK)
Via
Benzinga
Exposures
COVID-19
October Starts Positive
October 01, 2021
A lot of these moves are simply reactions to last month's excesses and they may not be predictive for October at all.
Via
Talk Markets
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Labcorp's At Home Collection Kit Gets EUA Nod For Combined COVID-19 and Flu Detection
October 01, 2021
The FDA has granted Emergency Use Authorization (EUA) to Laboratory Corp of America Holdings's (NYSE: LH) combined home collection kit to detect COVID-19 and...
Via
Benzinga
Exposures
COVID-19
Product Safety
BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial
October 01, 2021
BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial...
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.